Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Gilead Sciences, Inc. (NASDAQ: GILD).

Full DD Report for GILD

You must become a subscriber to view this report.


Recent News from (NASDAQ: GILD)

Trade Truce Shot Clock Keeps Ticking (Wall Street Breakfast Podcast)
Today's Top Stories: Stocks across the globe are flashing red; China's trade surplus with the U.S. jumped in November, and China's foreign ministry called in the U.S. ambassador on Sunday to lodge a "strong protest" over the arrest of Huawei CFO Meng Wanzhou in Vancouver. If you are...
Source: SeekingAlpha
Date: December, 10 2018 08:13
New Research Coverage Highlights Skyworks Solutions, Virtus Investment Partners, Altria Group, Gilead Sciences, Arthur J. Gallagher, and BP p.l.c - Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Dec. 10, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Skyworks Solutions, Inc. (NASDAQ:SWKS), Virtus Investment Partners, Inc. ...
Source: GlobeNewswire
Date: December, 10 2018 07:35
Wall Street Breakfast: Trade Truce Shot Clock Keeps Ticking
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). Stocks across the globe are flashing red, while U.S. equity futures were off to a softer start to the new week on ...
Source: SeekingAlpha
Date: December, 10 2018 07:02
It's official! O'Day takes top job at Gilead
Gilead Sciences (NASDAQ: GILD ) has named Roche ( OTCQX:RHHBY ) executive Daniel O’Day as its new chief executive officer, tapping an industry veteran to fill a management vacuum. He'll begin the job on March 1, 2019. More news on: Gilead Sciences, Inc., Roche Holding Ltd ADR, Roc...
Source: SeekingAlpha
Date: December, 10 2018 02:36
Gilead Sciences Names Daniel O'Day Chairman and Chief Executive Officer
-- Mr. O’Day Brings Global Pharmaceutical Leadership Experience Across Geographies and Therapeutic Areas -- -- Appointment Effective March 1, 2019 -- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its Board of Directors has named Daniel O’Day Ch...
Source: Business Wire
Date: December, 10 2018 01:00
WSJ: Gilead Sciences to hire Roche exec O'Day as its next CEO
Gilead Sciences (NASDAQ: GILD ) is expected to hire longtime Roche ( OTCQX:RHHBF , OTCQX:RHHBY ) executive Daniel O’Day to become its new CEO , possibly as soon as tomorrow, WSJ reports. More news on: Gilead Sciences, Inc., Roche Holding Ltd, Roche Holding Ltd ADR, Healthcare st...
Source: SeekingAlpha
Date: December, 09 2018 21:53
How To Retire At 62 With Just Half A Million
In the previous article that we wrote on our hypothetical couple - John and Lisa - we tried to demonstrate how they could retire in 10 years, starting with a modest savings of $300,000 at the age of 50 years that would grow to $1 Million by the time they actually retire at 60. We had assumed...
Source: SeekingAlpha
Date: December, 08 2018 09:43
Performance Review: Stocks That Topped My Factor-Based Quality Ranking Model
Background Last December, I wrote this article describing how I pick stocks to invest for the long run using a quality-focused ranking approach. The ranking model contained a few quantifiable factors covering different dimensions of business fundamentals, some of which I would like to reit...
Source: SeekingAlpha
Date: December, 04 2018 09:05
China National Medical Products Administration Approves Descovy® (Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
– Fixed-Dose Combination HIV Treatment Backbone Can Be Paired with Range of Third Agents – Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the China National Medical Products Administration (NMPA) has approved Descovy ® (emtricitabine 200 mg/tenofovir a...
Source: Business Wire
Date: December, 04 2018 08:30
China's National Medical Products Administration Approves Harvoni® (Ledipasvir/Sofosbuvir) for Treatment of Chronic Hepatitis C Virus Genotype 1-6
--Harvoni Offers Highly Effective, Short-Duration, Pan-Genotypic Treatment for Chinese Patients with HCV Infection-- --Harvoni Achieved Cure Rate (SVR12) of 100 Percent in Clinical Trial of Chinese Patients with Genotype 1-- Gilead Sciences, Inc. (NASDAQ: GILD) announced toda...
Source: Business Wire
Date: December, 04 2018 08:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-0872.7372.2272.8071.496,892,313
2018-05-1767.1067.6068.129967.105,946,194
2017-06-1365.6165.1565.6565.018,185,266
2017-06-1264.6065.4366.7064.5510,459,196
2017-06-0964.1164.7064.9463.959,338,911

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-12242,4361,260,51219.2331Cover
2018-12-11228,2191,118,68220.4007Cover
2018-12-10668,0812,266,71229.4736Cover
2018-12-07191,614764,85225.0524Cover
2018-12-06500,8191,395,80335.8803Short

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on GILD.


About Gilead Sciences, Inc. (NASDAQ: GILD)

Logo for Gilead Sciences, Inc. (NASDAQ: GILD)

Not available

 

Contact Information

 

 

Current Management

  • John C. Martin / President, CEO
  • John F. Milligan / CFO, COO

Current Share Structure

  • Market Cap: $87,832,619,202 - 05/16/2018
  • Issue and Outstanding: 1,300,260,832 - 04/30/2018

 


Recent Filings from (NASDAQ: GILD)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 09 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 26 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: March, 08 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: February, 27 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: February, 27 2018
Annual statement of changes in beneficial ownership of securities
Filing Type: 5Filing Source: edgar
Filing Date: February, 16 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 09 2018

 

 


Daily Technical Chart for (NASDAQ: GILD)

Daily Technical Chart for (NASDAQ: GILD)


Stay tuned for daily updates and more on (NASDAQ: GILD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: GILD)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in GILD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of GILD and does not buy, sell, or trade any shares of GILD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/